Skip to main content
. 2022 Apr 13;10(1):267–283. doi: 10.1016/j.gendis.2022.04.001

Figure 6.

Fig. 6

Treatment of Clo or Can decreased p65me2 and reduced NF-κB target gene expression in cancer cells. (A) Western blots, showing that treatment of Clo and Can decreased symmetric demethylation of p65, a PRMT5 substrate, in PDAC, CRC and BC cells. (B, C) ELISA assays, showing that secretion of TNFα (B) or IL8 (C) was significantly reduced in the condition media from cancer cells treated with either Clo or Can.